title: In reply.
authors.forename: Daniel K
authors.initials: DK
authors.lastname: Nishijima
authors.forename: James F
authors.initials: JF
authors.lastname: Holmes
authors.forename: Steven R
authors.initials: SR
authors.lastname: Offerman
authors.forename: Dustin W
authors.initials: DW
authors.lastname: Ballard
authors.forename: David R
authors.initials: DR
authors.lastname: Vinson
authors.forename: Uli K
authors.initials: UK
authors.lastname: Chettipally
authors.forename: Adina S
authors.initials: AS
authors.lastname: Rauchwerger
authors.forename: Mary E
authors.initials: ME
authors.lastname: Reed
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D006259:Craniocerebral Trauma / Q000150:complications*; D005260:Female; D006801:Humans; D020300:Intracranial Hemorrhages / Q000209:etiology*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D013988:Ticlopidine / Q000031:analogs & derivatives*; D014859:Warfarin / Q000009:adverse effects*
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D013988:Ticlopidine